Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)

Guo, Jun; Qin, Shukui; Liang, Jun; Lin, Tongyu; Si, Lu; Chen, Xiaohong; Chen, Zhihong; Cui, Chuanliang; Du, Nan; Fan, Yun; Gu, Kangsheng; Li, Fang; Li, Junling; Li, Yongheng; Liang, Houjie; Liu, Jiwei; Lu, Man; Lü, Aiping; Kang, Nan; Niu, Xiaohui; Pan, Hongming; Ren, Guoxin; Ren, Xiubao; Shu, Yongqian; Song, Xin; Tao, Min; Wang, Baocheng; Wei, Wenbin; Wu, Di; Wu, Lingying; Wu, Aiwen; Xu, Xiaolin; Zhang, Junyi; Zhang, Xiaoshi; Zhang, Yiping; Zhu, Huiyan

doi:10.21037/cco.2015.12.02

Cited by 70 publications

(87 citation statements)

References 220 publications

(180 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of melanoma is rising globally, including throughout China (Guo et al, ). Based on the anatomic location, melanomas can be classified into several subtypes, including cutaneous melanoma that occur on skin, acral melanoma that occur on the hands and feet, mucosal melanoma, the rarest subtype, which arises from melanocytes in the mucosal lining of internal tissues, and uveal melanoma which develops from melanocytes in the uveal tract of the eye (Rager, Bridgeford, & Ollila, ).…”

Section: Introductionmentioning

confidence: 99%

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling

Zou

Ou²,

Ren

et al. 2020

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

The incidence of melanoma is rising globally including China. Comparing to Caucasians, the incidence of non‐cutaneous melanomas is significantly higher in Chinese. Herein, we performed genomic profiling of 89 Chinese surgically resected primary melanomas, including acral (n = 54), cutaneous (n = 22), and mucosal (n = 13), by hybrid capture‐based next‐generation sequencing. We show that mucosal melanomas tended to harbor more pathogenic mutations than other types of melanoma, though the biological significance of this finding remains uncertain. Chromosomal arm‐level alterations including 6q, 9p, and 10p/q loss were highly recurrent in all subtypes, but mucosal melanoma was significantly associated with increased genomic instability. Importantly, 7p gain significantly correlated with unfavorable clinical outcomes in non‐cutaneous melanomas, representing an intriguing prognostic biomarker of those subtypes. Furthermore, focal amplification of 4q12 (KIT, KDR, and PDGFRα) and RAD51 deletion were more abundant in mucosal melanoma, while NOTCH2 amplification was enriched in acral melanoma. Additionally, cutaneous melanomas had higher mutation load than acral melanomas, while mucosal melanomas did not differ from other subtypes in mutation burden. Together, our data revealed important features of acral and mucosal melanomas in Chinese including distinctive driver mutation pattern and increased genomic instability. These findings highlight the possibilities of combination therapies in the clinical management of melanoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling

Zou

Ou²,

Ren

et al. 2020

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…3 Evidence suggests that the use of local and regional anesthetics is associated with improved overall survival in surgically treated patients with colorectal carcinoma and breast cancer. 2 Therefore, local anesthetics are implicated as novel agents for the treatment of cancer that may avoid the side effects associated with the currently available chemotherapeutic agents. 2 Therefore, local anesthetics are implicated as novel agents for the treatment of cancer that may avoid the side effects associated with the currently available chemotherapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation

Jiao

Wang

Zhong

2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

The melanoma is responsible for the majority of all skin cancer–related deaths worldwide. Evidence suggests that local anesthetics provide some benefit in the treatment of cancer via inhibition of cellular proliferation, invasion and migration. However, the potential antiproliferative effects of local anesthetics in the treatment of melanoma remain to be elucidated. In this study, we investigated the antiproliferative effects and underlying mechanism of the commonly used local anesthetic (lidocaine) on melanoma cells. A375 melanoma cells were treated by lidocaine or vemurafenib. Cell Counting Kit‐8, histological staining, flow cytometric analysis, immunohistochemical staining, and Western blot analyses were carried out to test the effects of lidocaine and vemurafenib on A375 cells. BALB/C‐nu/nu mice intraperitoneally injected with A375 cells were treated by lidocaine, and then tumor volume and weight were calculated. Lidocaine exhibited vemurafenib‐like effects totally. Lidocaine inhibited A375 melanoma cell proliferation in a dose‐ and time‐dependent manner and colony formation also showed a dose‐dependent inhibition. Lidocaine treatment resulted in the arrest of cell‐cycle progression in the G1 phase and inhibited Ki‐67 expression in a dose‐dependent manner. This effect was associated with inhibited extracellular signal–regulated kinase (ERK) phosphorylation. In vivo experiments revealed that intravenous injections of lidocaine suppressed tumor volume and weight. Lidocaine inhibits melanoma cell proliferation in a dose‐ and time‐dependent manner via a mechanism that may involve inhibition of the ERK signaling pathway. Thus, lidocaine may provide some benefit for the treatment of melanoma.

show abstract

“…We found that the expression of GEF-H1 in melanoma tissues was much higher than that in adjacent tissues of the same person. We classified 60 patients with melanoma according to the literature, 22 , 23 and the results showed that the expression of GEF-H1 was correlated with melanoma prognosis ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma

Shi

Guo

Zhang

et al. 2016

BTT

View full text Add to dashboard Cite

Guanine nucleotide exchange factor H1 (GEF-H1), which couples microtubule dynamics to RhoA activation, is a microtubule-regulated exchange factor. Studies have shown that GEF-H1 can be involved in various cancer pathways; however, the clinical significance of GEF-H1 expression and functions in melanoma has not been established. In this study, we investigated the relationship between clinical outcomes and GEF-H1 functions in melanoma. A total of 60 cases of different grades of melanoma samples were used to detect the expression of GEF-H1. Results showed that both messenger RNA and protein levels of GEF-H1 were significantly higher in high-grade melanomas. Furthermore, patients with high GEF-H1 expression had a shorter overall survival (22 months) than patients with low level of GEF-H1 expression (33.38 months). We also found that GEF-H1 can promote the proliferation and metastasis of melanoma cells. In summary, these results suggested that GEF-H1 may be a valuable biomarker for assessing the degree and prognosis of melanoma following surgery.

show abstract

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)

Cited by 70 publications

References 220 publications

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling

Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation

Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma

Contact Info

Product

Resources

About